Corporate Symposia - Non-CME


BACE Inhibitors for the Treatment of Alzheimer’s Disease

Monday, July 17 | 6 – 8:30 p.m.

Grange St. Paul’s Hotel, 10 Godliman Street, London, (Shuttle service available beginning at 5 p.m. from the east entrance of ExCeL London)

Through five engaging and interactive sessions, presenters will share insights on BACE inhibition as a therapeutic approach, provide perspective on BACE inhibitor development and advise on how research may help shape the Alzheimer's disease landscape. Refreshments will be provided.

Sponsored by: Eisai

CSF Biomarkers in AD: Unity and Clarity in the New Testing Paradigm

Monday, July 17 | 6:30 - 8 p.m.

The East Wintergarden, 43 Bank Street, Canary Wharf, E14 5NX

The symposium will address the status of CSF biomarkers and the challenges that need to be overcome to create a robust, clear and unified testing paradigm for the diagnosis, prognosis and monitoring of Alzheimer’s disease.

Sponsored by: Roche

Agitation in Alzheimer’s Disease: Understanding Neurobiology, Impact and Therapeutic Targets

Monday, July 17 | 7 – 8:30 p.m.

Grange City Hotel, London

Interactive symposium focusing on increasing understanding of agitation in Alzheimer’s disease, including diagnosis and assessment, the unmet needs of patients and caregivers, current theories on the neurobiology of agitation and other neuropsychiatric symptoms and potential therapeutic targets.

Sponsored by: Avanir Pharmaceuticals Inc. and Otsuka Pharmaceutial Europe Ltd



The Continuum of Alzheimer’s Disease: What Are the Implications for the Path to 2025?

Tuesday, July 18 | Noon – 1:45 p.m.

Auditorium, The Crystal, Royal Victoria Docks, London

This symposium will explore the current understanding of Alzheimer’s Disease clinical presentations and assessment tools, as well as pathophysiology and available biomarkers as a continuum. Conceptualizing Alzheimer’s Disease as a continuum may assist with creating a more uniform approach in both research and clinical practice on the path to 2025.

Sponsored by: Eli Lilly and Company

The Emerging Picture of Early Alzheimer’s Disease: Interactive Case Discussion and Implications for Clinical Practice

Tuesday, July 18 | 6 – 9 p.m.

Grange St Paul’s Hotel, Wren & Shakespeare Room, 10 Godliman Street, London

This symposium centers on a patient case to illustrate how the current understanding of early Alzheimer’s disease (AD) translates into clinical practice. You will be invited to interact with the faculty on key topics, such as cognitive assessment, diagnostic biomarker tools, and clinical management of early AD.

Sponsored by: Biogen

Before the Symptoms: Prospects for Intervention in Preclinical Alzheimer’s Disease

Tuesday, July 18 | Light Refreshments, 6:30 – 7:30 p.m. / Presentations, Panel Discussion and Interactive Q and A 7:30 – 9:30 p.m.

Grange Tower Bridge Hotel, Trinity Suite, -2 Floor, London

Leading experts will review the clinical and pathological features that define the AD continuum, discuss the scientific rationale and strategies for intervention before memory decline and consider approaches to conducting trials in preclinical disease.

Sponsored by: Pfizer Inc.



Biomarkers in the Dementia Spectrum: Moving the Field to an Etiological Diagnosis

Tuesday, July 18 | Refreshments 6 – 6:45 p.m. / Introduction and Presentations 6:45 p.m. – 8 p.m.

Auditorium, Crystal Hotel, Royal Victoria Docks, London

Over the last decade, the definition of AD has evolved considerably. It is widely recognised that there is a pathological and clinical continuum and newest guidelines reflect this thinking. We will discuss this new lexicon of definitions and explore the application of biomarkers to derive an etiological diagnosis and impact patient management in clinical practice.

Sponsored by: GEHC

Advances in the Management of Agitation in Alzheimer’s Dementia

Wednesday, July 19 | 12:15 – 1:45 p.m.

Crystal Hotel, Royal Victoria Docks, London

The burden of neuropsychiatric symptoms in Alzheimer’s dementia will be discussed, with focus on agitation and its management. Consideration will be given to care settings and unmet needs. Ongoing pharmacological late-stage developments for treating agitation in Alzheimer’s dementia will also be reviewed.

Sponsored by: Otsuka Pharmaceutical Development & Commercialization, Inc. and H. Lundbeck A/S

The Dementia Exchange: Conversations and Connections

Wednesday, July 19 | 6 – 9 p.m.

Grange Tower Bridge Hotel, Trinity Ballroom, 45 Prescott Street, London

Connect with us for a dynamic, impassioned discussion with world-renowned leaders in dementia research and management. In this setting, each speaker will aim to increase your curiosity and inspire you to form new connections to better treat dementia. Space is limited, please pre-register.

Sponsored by: Axovant


Join the Conversation #AAIC18






> 1200px
> 992px
> 768px
< 767px